Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Treats seizures. Also treats the manic phase of bipolar disorder (manic-depressive illness) and helps prevent migraine headaches. This medicine is an anticonvulsant.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 21 to 40 of 70

Migraine in Adults: Preventive Pharmacologic Treatments [Internet]

To assess comparative effectiveness and safety of preventive pharmacologic treatments for community-dwelling adults with episodic or chronic migraine.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: April 2013
Show search results within this document

Borderline Personality Disorder: Treatment and Management

The guideline on Borderline Personality Disorder, commissioned by NICE and developed by the National Collaborating Centre for Mental Health, sets out clear, evidence- and consensus-based recommendations for healthcare staff on how to treat and manage borderline personality disorder.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2009
Show search results within this document

Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet]

To assess efficacy, comparative effectiveness, and harms of psychological and pharmacological treatments for adults with posttraumatic stress disorder (PTSD).

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: April 2013
Show search results within this document

A Systematic Review of Prevention and Intervention Strategies for Populations at High Risk of Engaging in Violent Behaviour: Update 2002–8

It has been estimated that violence accounts for more than 1.6 million deaths worldwide each year and these fatal assaults represent only a fraction of all assaults that actually occur. The problem has widespread consequences for the individual and for the wider society in physical, psychological, social and economic terms. A wide range of pharmacological, psychosocial and organisational interventions have been developed with the aim of addressing the problem. This review was designed to examine the effectiveness of these interventions when they are developed in mental health and criminal justice populations.

Health Technology Assessment - NIHR Evaluation, Trials and Studies Coordinating Centre (UK).

Version: February 2012
Show search results within this document

Suicide Prevention Interventions and Referral/Follow-Up Services: A Systematic Review [Internet]

Suicide is the tenth leading cause of death in the United States (US), with nearly 100 suicides occurring each day and over 36,000 dying by suicide each year. Among Veterans and current military, suicide is a national public health concern. Recent estimates suggest current or former military represent 20 percent of all known suicides in the US and the rate of suicides among Veterans utilizing Veterans Health Administration (VHA) services is estimated to be higher than the general population. The enormity of the problem has led to several major public health initiatives and a growth in research funding for suicide prevention.

Evidence-based Synthesis Program - Department of Veterans Affairs.

Version: March 2012
Show search results within this document

Dementia: A NICE-SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care

This guideline has been developed to advise on supporting people with dementia and their carers in health and social care. The guideline recommendations have been developed by a multidisciplinary team of health and social care professionals, a person with dementia, carers and guideline methodologists after careful consideration of the best available evidence. It is intended that the guideline will be useful to practitioners and service commissioners in providing and planning high-quality care for those with dementia while also emphasising the importance of the experience of care for people with dementia and carers.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2007
Show search results within this document

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet]

Atypical antipsychotic agents are used to treat the symptoms of schizophrenia and bipolar disorder. The purpose of this review is to help policy makers and clinicians make informed choices about their use. Given the prominent role of drug therapy in psychiatric disease, our goal is to summarize comparative data on efficacy, effectiveness, tolerability, and safety. Ten atypical antipsychotics are currently available in the United States and Canada. Clozapine, the prototypic atypical antipsychotic, was introduced in 1989. Since then, 9 other atypical antipsychotics have been brought to market: risperidone (1993), risperidone long-acting injection (2003), olanzapine (1996), quetiapine (1997), ziprasidone (2001), aripiprazole (2002), extended-release paliperidone (2006), asenapine (2009), iloperidone (2009), and paliperidone long-acting injection (2009).

Drug Class Reviews - Oregon Health & Science University.

Version: July 2010
Show search results within this document

Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies

This meta-analysis concluded valproic acid treatment during pregnancy was associated with reduced IQ scores in children of mothers with epilepsy; carbamazepine did not appear to be associated with reduced verbal IQ and full-scale IQ scores. Methodological weaknesses in the included studies and limitations in the review process made the reliability of the authors? conclusions unclear.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

No evidence of efficacy of valproate preparations for treatment of agitation in people with dementia

An updated review (October 2008) of valproate treatment of agitation in demented patients failed to show any improvement in agitation among treated patients compared with those not receiving treatment, and also demonstrated a higher rate of harmful effects, such as falls,infections and gastrointestinal disorders (diarrhoea, nausea) among those receiving valproate preparations. Although further research on the value of valproate preparations is indicated, current evidence does not support use of this drug to control agitation of people with dementia.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

Valproate for preventing migraine attacks in adults

Various medicines, collectively termed 'antiepileptics', are used to treat epilepsy. For several years, some of these drugs have also been used for preventing migraine attacks. For the present review, researchers in The Cochrane Collaboration reviewed the evidence about the effects of valproate (valproic acid or sodium valproate or a combination of the two) in adult patients (≥ 16 years of age) with 'episodic' migraine (headache on < 15 days per month). They examined research published up to 15 January 2013 and found 10 relevant studies. Compared with placebo, valproate reduced the frequency of migraine headaches by approximately four per month (two studies, 63 participants). Patients were also more than twice as likely to reduce the number of their migraine headaches by 50% or more with valproate than with placebo (five studies, 576 participants). Side effects associated with valproate were common but generally mild; valproate can, however, cause birth defects and so should be used with caution in women of childbearing age. Further research is needed comparing valproate with other active drugs used for preventing migraine attacks.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Anticonvulsant drugs for migraine prophylaxis

1. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010610. DOI: 10.1002/14651858.CD010610.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Side effects of phenobarbital in epilepsy: a systematic review

AIM: In recent years, phenobarbital, as an antiepileptic drug, has become less popular based on adverse events, especially cognitive and behavioural side effects. Despite the development of better tolerated new generation AEDs, phenobarbital is still widely used particularly in developing countries because of its low cost. The purpose of this review was to: (i) investigate whether phenobarbital can be safely used as an antiepileptic drug and (ii) determine the questions which need to be addressed in order to comprehensively and adequately evaluate the safety of phenobarbital for the treatment of epilepsy.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Seizure prophylaxis in patients with brain tumors: a meta-analysis

OBJECTIVE: To assess whether antiepileptic drugs (AEDs) should be prescribed to patients with brain tumors who have no history of seizures.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2004

Is there evidence to support the use of antiepileptic drugs for the primary and secondary prevention of seizures after stroke?

Seizures (epileptic attacks) after stroke are a major clinical problem. It is unclear whether antiepileptic drugs are effective in preventing seizures after stroke in adults. This review searched in August 2013 for high quality evidence to help clarify this problem. We found only one high quality clinical trial that looked at whether antiepileptic drugs may be more effective than placebo in preventing seizures after stroke.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2014

Interventions for Adult Offenders With Serious Mental Illness [Internet]

To comprehensively review the evidence for treatments for offenders with serious mental illness (i.e., schizophrenia, schizoaffective disorder, bipolar disorder, or major depression) in jail, prison, or forensic hospital, or transitioning from any of these settings to the community (e.g., home, halfway house).

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: August 2013
Show search results within this document

Psychosis with Coexisting Substance Misuse: Assessment and Management in Adults and Young People

This clinical guideline covers the assessment and management of adults and young people (aged 14 years and older) who have a clinical diagnosis of psychosis (schizophrenia, bipolar disorder or other affective psychosis) and coexisting substance misuse (harmful use of any psychotropic substance including alcohol and legal or illicit drugs).

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2011
Show search results within this document

Antenatal and Postnatal Mental Health: The NICE Guideline on Clinical Management and Service Guidance

This guideline has been developed to advise on the clinical management of and service provision for antenatal and postnatal mental health. The guideline recommendations have been developed after careful consideration of the best available evidence by a multidisciplinary team of healthcare professionals, women who have experienced mental health problems in the antenatal or postnatal period and guideline methodologists. It is intended that the guideline will be useful to clinicians and service commissioners in providing and planning high-quality care for women with antenatal and postnatal mental health problems while also emphasising the importance of the experience of care for women and their families and carers.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2007
Show search results within this document

Therapies for Children With Autism Spectrum Disorders

The Vanderbilt Evidence-based Practice Center systematically reviewed evidence on therapies for children ages 2 to 12 with autism spectrum disorders (ASDs). We focused on treatment outcomes, modifiers of treatment effectiveness, evidence for generalization of outcomes to other contexts, and evidence to support treatment decisions in children ages 0–2 at risk for an ASD diagnosis.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: April 2011
Show search results within this document

Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-Specialist Settings

This clinical guideline covers the management of neuropathic pain conditions in adults (aged 18 or over) in primary care and secondary care, excluding specialist pain management clinics. The aim of the guideline is to provide clear recommendations to healthcare professionals in non-specialist settings on the treatment and management of neuropathic pain. This includes recommendations on appropriate and timely referral to specialist pain services and/or condition-specific services. In general, regarding neuropathic pain as a ‘blanket condition’, irrespective of the underlying cause, is helpful and practical for both non-specialist healthcare professionals and patients. However, condition-specific recommendations and research recommendations have been made where robust evidence on clinical and cost effectiveness exists for specific conditions, or where the evidence is clearly uncertain. The guideline excludes acute pain arising directly (in the first 3 months) from trauma or orthopaedic surgical procedures.

NICE Clinical Guidelines - National Institute for Health and Clinical Excellence (UK).

Version: March 2010
Show search results within this document

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses [Internet]

Optimizing drug-related health outcomes and the cost-effective use of drugs is a goal of the Canadian Agency for Drugs and Technologies in Health (CADTH). Where possible, CADTH builds on existing applicable Canadian and international initiatives and research.

CADTH Optimal Use Report - Canadian Agency for Drugs and Technologies in Health.

Version: December 2011
Show search results within this document

Systematic Reviews in PubMed

See all (272)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...